Palafer® CF
Prodotto naturale per la salute autorizzato in Canada
- Titolare
- Bausch & Lomb Inc.
- NPN o DIN-HM
- 01923455
- Stato
- Licenza attiva
- Data della licenza
- 27 marzo 2009
- Data di revisione
- 7 febbraio 2024
- Forma
- Capsule
- Via di somministrazione
- Orale
- Tipo di domanda
- DIN de transition
Se questo prodotto fosse venduto in Francia
Nessun punto rilevato secondo le norme che applichiamo.
Si calcola una quantità giornaliera solo per una posologia orale esplicita per adulti, espressa al giorno e in un’unità solida corrispondente alla forma del prodotto. Unità ambigue, liquidi, polveri e dosi pediatriche non vengono estrapolati. Una quantità non calcolata non viene confrontata con i limiti di dose. Questa analisi non costituisce un’autorizzazione alla vendita in Francia né una valutazione di sicurezza o efficacia.
Composizione
Composizione medicinale non indicata.
Ingredienti non medicinali
Rouge FD & C #3, Stéarate de magnésium, FD & C Jaune no. 6, Talc, Eau purifiée, Lactose Monohydrate, Jaune D & C No. 10, Dioxyde de titane, Lauryl sulfate de sodium, Sucrose, Gélatine, Povidone, FD & C bleu #1, FD&C Red No. 2, Dioxyde de silicium
Dosi raccomandate in Canada
| Popolazione | Età | Quantità per assunzione | Frequenza |
|---|---|---|---|
Adulti Tradotto automaticamente dal francese. Vedi l’originaleAdultes | Non precisata Tradotto automaticamente dal francese. Vedi l’originaleNon précisée | Traduzione non disponibile. Testo originale, lingua: francese. 1 Capsule | Non precisata Tradotto automaticamente dal francese. Vedi l’originaleNon précisée |
Bambini Tradotto automaticamente dal francese. Vedi l’originaleEnfants | Traduzione non disponibile. Testo originale, lingua: francese. minimum : 12 ans | Traduzione non disponibile. Testo originale, lingua: francese. 1 Capsule | Non precisata Tradotto automaticamente dal francese. Vedi l’originaleNon précisée |
Usi autorizzati in Canada
Traduzione non disponibile. Testo originale, lingua: inglese.
Iron therapy. For the prevention and treatment of iron and folic acid deficiencies. For the prevention and treatment of iron deficiency and iron deficiency anemia. Mineral supplement. Vitamin supplement. Helps reduce the risk of neural tube defects when taken daily prior to becoming pregnant and during early pregnancy. A factor in the maintenance of good health. Helps the body to metabolize proteins and fat. Helps in the development and maintenance of bones, cartilage, teeth and gums. Helps to form red blood cells and helps in their proper function. Helps in connective tissue formation and wound healing. An antioxidant for the maintenance of good health. Helps to prevent Vitamin C deficiency. Helps to prevent folate deficiency.
Additional information for health care practitioners: Prophylactic administration of Palafer CF should be discontinued at term. Iron therapy alone should be administered after parturition. Iron poisoning is rare in adults but serious acute poisoning in children can result from ingestion of doses in excess of 1 g. Doses of 1 g should be considered as toxic in children and therapy instituted as soon as possible. Serum iron levels above 500 mcg/100 mL can be presumptive evidence of poisoning; severe poisoning is usually associated with levels well above 1000 mcg/100mL. Symptoms may occur within about 30 minutes or may be delayed several hours. They are largely those of gastrointestinal irritation and necrosis with vomiting, diarrhea, tarry stools, hematemesis, fast and weak pulse, lethargy, low blood pressure, coma and signs of peripheral circulatory collapse. There may be a transient period of apparent recovery after 4 to 6 hours followed by a second crisis characterized by cyanosis, pulmonary edema, circulatory collapse, convulsion, and coma may then occur followed by death in 12 to 48 hours. Treatment; Milk should be given immediately and vomiting induced. Eggs and milk should then be fed (to form Iron-protein complexes) until it is possible to perform gastric lavage with 1% sodium bicarbonate solution (to convert the iron to a less soluble form). Gastric lavage should not be performed after the first hour of iron ingestion because of the danger of perforation due to gastric necrosis. If an iron-chelating agent such as deferoxamine mesylate is available, it should be utilized. BAL (dimercaprol) should not be used because it may form a toxic complex. Measures to combat shock, dehydration, blood loss and respiratory failure may be necessary.Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.
Avvertenze in Canada
Traduzione non disponibile. Testo originale, lingua: inglese.
Cautions and Warnings : This package contains enough drug to seriously harm a child.
Additional information for health care practitioners: Where anemia exists, its nature should be established and underlying causes determined. Prolonged administration of iron should be avoided except in patients with continued bleeding or repeated pregnancies. In infants, large chronic doses of iron may so interfere with the assimilation of phosphorous as to cause severe rickets. Orally administered iron salts may aggravate existing disorders, such as peptic ulcer, regional enteritis and ulcerative colitis. They may not be absorbed in patients with steatorrhea and those who have had a partial gastrectomy. Before initiating parenteral iron therapy, it is advisable to give test doses to help detect sensitivity. Iron overload can occur in patients given an excess of parenteral iron, as well as those with hemoglobinopathies or other refractory anemias which might be erroneously diagnosed as iron-deficiency anemia. Do not administer oral iron preparations concomitantly with parenteral iron. Iron with tetracyclines binds in equal molecular ratio thus preventing absorption of tetracyclines. Warn patients that iron is toxic when overdoses are ingested by children. Severe reactions, including fatalities, have resulted. Concomitant administration of antacids containing aluminum and magnesium salts may impair the absorption of iron.
Do not use except under the care of a physician. Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if you have a peptic ulcer, regional enteritis or ulcerative colitis.Traduzione non disponibile. Testo originale, lingua: inglese.
Contra-Indications : N/A
Additional information for health care practitioners: Hemosiderosis, hemochromatosis. Iron compounds are also contraindicated in the treatment of hemolytic anemias unless an iron-deficient state also exists, since storage of iron with a possible exogenous hemosiderosis can result.Traduzione non disponibile. Testo originale, lingua: inglese.
Known Adverse Reactions : Some people may experience constipation, diarrhea and/or vomiting.
Additional information for health care practitioners: Oral ingestion of iron preparations may be associated with gastrointestinal discomfort (such as nausea) and dose-related bowel effects (such as constipation, diarrhea, and/or
vomiting). Untoward effects usually subside with continuation of therapy or by iron ingestion with or after meals. Parenteral
iron administration can cause nausea, vomiting, and such acute allergic reactions as chills and fever, arthralgia, urticaria,
and asthma. Occasional pain and staining of the skin at the site of the injection may occur. Severe anaphylactoid reactions
with some deaths have been reported in the literature. Although i.m. administration of iron dextran injections has caused sarcoma in laboratory animals, induced malignancy in man has never been observed.Fonte
Scheda ufficiale Health Canada, licenza 01923455
Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.
Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPSNH)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.
Elenco nella revisione ufficiale del (registro: Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze).
Elenco rilevato nel 2024. Fotografi la confezione per verificare eventuali modifiche. Fotografare la confezione